• Impact of prebiopsy MRI on prostate cancer staging: Results from the Norwegian Prostate Cancer Registry 

      Haug, Erik Skaaheim; Myklebust, Tor Åge; Juliebø-Jones, Patrick; Reisæter, Lars Anders Rokne; Aas, Kirsti; Berg, Arne Stenrud; Muller, Christoph Rainer; Hofmann, Bjørn Morten; Størkersen, Øystein; Nilsen, Kim L.; Johannessen, Tom Børge; Beisland, Christian (Peer reviewed; Journal article, 2023)
      The aim of this study is to evaluate the 2015 introduction of prebiopsy magnetic resonance imaging of the prostate (MRI-P) as the standard of care for diagnosing prostate cancer (PCa) by the Norwegian public health care ...
    • Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P) 

      Löffeler, Sven; Bertilsson, Helena Maria; Müller, Christoph Rainer; Aas, Kirsti; Haugnes, Hege Sagstuen; Aksnessæther, Bjørg Yksnøy; Pesonen, Maiju; Thon, Kristian; Tandstad, Torgrim; Murtola, Teemu; Poulsen, Mads Hvid Aaberg; Nordstrøm, Tobias; Vigmostad, Maria Nyre; Ottosson, Fredrik; Holmsten, Karin; Christiansen, Ola B.; Slaaen, Marit; Haug, Erik Skaaheim; Storås, Anne Holck; Asphaug, Lars; Rannikko, Antti; Brasso, Klaus (Peer reviewed; Journal article, 2024)
      Background Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs ...
    • Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients 

      Gerdtsson, Axel; Torisson, Gustav; Thor, Anna; Grenabo Bergdahl, Anna; Almås, Bjarte; Håkansson, Ulf; Törnblom, Magnus; Negaard, Helene Francisca Stigter; Glimelius, Ingrid; Halvorsen, Dag; Karlsdottir, Åsa; Haugnes, Hege Sagstuen; Larsen, Signe Melsen; Holmberg, Göran; Wahlqvist, Rolf; Tandstad, Torgrim; Cohn-Cedermark, Gabriella; Ståhl, Olof; Kjellman, Anders (Peer reviewed; Journal article, 2023)
      Objective To validate Vergouwe's prediction model using the Swedish and Norwegian Testicular Cancer Group (SWENOTECA) RETROP database and to define its clinical utility. Materials and methods Vergouwe's prediction ...